ETRA Electra Therapeutics, Inc. - Common stock
NASDAQ close Oct 5, 2026ETRA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ETRA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC | Sept. 25, 2026 | 11.00% | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 5 insiders · 3 officers · 3 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Quehuong (Kathy) Dong | President & CEO | Sept. 21, 2026 C | 455,484 | 0 | 0 | $0 |
| Graham Parry | Chief Scientific Officer | Sept. 21, 2026 C | 85,504 | 0 | 0 | $0 |
| Gary S. Koe | Chief Technical Officer | Sept. 21, 2026 C | 63,656 | 0 | 0 | $0 |
| Nancy Stagliano | Director | Sept. 21, 2026 C | 255,635 | 0 | 0 | $0 |
| GORDON CARL L | Director | Sept. 21, 2026 C | 1,758,279 | 2 | 0 | $19,999,995 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.